IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks.
At Snapdragon Chemistry, now part of Cambrex, our chemists specialize in creating custom solutions and technologies to take on your toughest process development and production challenges. This includes expertise in designing and building reactors that enable seamless technology transfer as a process scales up for commercial manufacturing.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
If you’re looking to outsource drug product development to a CDMO, you need a collaborative partner who will engage you deeply to understand the unique needs of your project.
From pre-formulation to commercial manufacturing and packaging, you can trust Cambrex to deliver your complex dosage forms with the perfect combination of technology, expertise, and collaboration.
We are equipped to take on projects at any size or scale, offering established pediatric formulation and development expertise and to-scale manufacturing capabilities.
Biopharma companies at all stages of development, rely on our expertise and broad capabilities to produce the clinical trial supply of drug products they need, when they need them.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
Cambrex offers a comprehensive suite of testing services for complex biopharmaceuticals including standalone analytical R&D, method validation, release testing, ICH stability, and routine QC testing.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
COVID-19 put life sciences supply chains under unprecedented pressure. Almost overnight, the long, global supply chains created in an era of easy cross-border trade were hit by national lockdowns that made it harder to keep getting products to patients. The experience forced companies to consider the effect of globalization on supply chain resilience, driving growing interest in reshoring operations.
COVID-19 confirmed theoretical concerns about supply chain resilience at a time of global workforce disruption and surging demand for particular pharmaceutical products.
To understand how that experience is shaping attitudes toward resilience, Informa Pharma Intelligence and Cambrex surveyed 117 leaders, mainly from biopharma companies. Around half of the respondents outsourced at least part of their supply chain to a contract development and manufacturing organization (CDMO).
Read our whitepaper to learn how the industry’s view on supply chain resiliency have changed, and the steps companies are taking to better navigate future obstacles.
Thank you for your interest in our content.
While other vendors within the pharmaceutical value chain have lagged in developing actionable, time-based sustainability programs, Cambrex has implemented Environmental, Social, and Governance (ESG) programs aligned to our corporate goals, including top-line growth, cost reduction, and increased employee productivity – driving more value for us and our clients.
Cambrex and Citeline surveyed 100 industry leaders to see how they use the capabilities of contract development and manufacturing organizations (CDMOs) and onshoring to advance their development processes. Watch this live webinar to hear Cambrex’s Frank Ferrante and SCxCMC Solutions’ Kevin Bittorf discuss the results and evolving trends.
Our infographic, created in conjunction with Citeline, explores current partnership preferences among life sciences organizations, along with onshoring trends that have greatly affected the industry, using data from a recent Citeline survey of senior-level executives in the space.